Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs Oak

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

OakFactor scores not reassessed.
Site position #213

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 63.2/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

Before comparing the headline prices, the No BS RX review and the Oak review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, No BS RX vs Open Water Rx and Oak vs Ro compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +34
92
58
Dose & formulationNo BS RX +28
90
62
Clinical oversightNo BS RX +6
72
66
Labs & monitoringNo BS RX +10
68
58
FulfillmentNo BS RX +6
94
88
Contract termsNo BS RX +26
74
48
No BS RX · top barOak · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXOak
WeighScore82.8/10063.2/100
GradeB−C
Site position#23#213
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separatelyFrom $119/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separatelyFrom $185/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified
CoverageConfirm program availability for your stateConfirm selected treatment and state: homepage promotes a 50-state provider network, while terms say 45 states or certain states
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
Oak

Site position #213 · C

Factor scores not reassessed.

Strengths

  • Current semaglutide and tirzepatide product pages explicitly identify the twelve-month term behind advertised starting rates
  • Monthly and three-month plans have no cancellation fee before the next charge under the current refund section
  • The policy specifies a medical-stop exception, prepaid future-month refund calculation and a limit on quarterly-plan discount repayment
  • Branded pens and Oral Wegovy tablets are now advertised alongside compounded injections; availability and exact prices require confirmation

What to consider

  • The $119/$185 rates do not establish a monthly debit, dose-independent price or usable shipment supply
  • Leaving a six- or twelve-month quarterly plan early can repay discounts on months received, capped at one quarterly payment
  • Orders already sent to the pharmacy are final; stopping the account does not refund them
  • The same terms page retains inconsistent company names, membership-fee language and state-availability statements
  • The public material reviewed did not establish the assigned medical practice, individual prescriber or dispensing pharmacy legal name and address

Featured provider

Oak

Factor scores not reassessed.

Oak scores 63.2/100 (C). Oak advertises compounded semaglutide from $119 and tirzepatide from $185 per month on twelve-month plans; compare the actual payment schedule and discount repayment terms before choosing a longer commitment.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard